Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data
https://doi.org/10.47360/1995-4484-2020-691-694
Abstract
Objective. To assess the duration of remission or inactive disease status in patients with achieved partial remission due to treatment with adalimumab (ADA) after it discontinuation.
Materials and methods. A dynamic observation was conducted of 26 patients with ankylosing spondylitis with partial remission achieved due to prolonged use (for 24 months or more) of subcutaneous injections of 40 mg ADA once every two weeks. The discontinuation of ADA was carried out after a 3-4 month period of its use in de-escalation mode in the form of 1 injection (40 mg) once every 4 weeks. After discontinuation of ADA, patients continued to take non-steroidal anti-inflammatory drugs, sulfasalazine at a dose of 1.5-2 g per day (11 patients) and methotrexate 10 mg per week (3 patients). Assessment of the clinical, laboratory and ultrasonographic parameters of ankylosing spondylitis was carried out in 3, 6 and 12 months after the abolition of the ADA.
Results and discussion. Among the observed patients, partial clinical remission of ankylosing spondylitis maintained after 6 months in 12 (46.2%) patients, and after 12 months - in 10 (38.5%). A low degree of ankylosing spondylitis activity (BASDAI <4) was maintained for 6 months after the abolition of ADA in 14 (53.8%) patients, and after 12 months - in 12 (46.2%).
Conclusion. Within 12 months after cancellation of ADA, ankylosing spondylitis exacerbation was observed in 53.8% of patients with initially achieved partial clinical remission.
About the Authors
A. V. Petrov
Medical Academy named after S.I. Georgievsky of Vernadsky CFU
Russian Federation
Competing Interests: not
Russian Federation
Andrey V. Petrov
295051, Simferopol, Lenin boulevard, 5/7
Competing Interests: not
Ya. O. Shevnina
Crimean Republican Clinical Hospital named after N.A. Semashko
Russian Federation
Competing Interests: not
Russian Federation
Yana O. Shevnina
295017, Simferopol, Kievskaya str., 69
Competing Interests: not
A. S. Gaffarova
Medical Academy named after S.I. Georgievsky of Vernadsky CFU
Russian Federation
Competing Interests: not
Russian Federation
Anife S. Gaffarova
295051, Simferopol, Lenin boulevard, 5/7
Competing Interests: not
N. V. Matveeva
Medical Academy named after S.I. Georgievsky of Vernadsky CFU
Russian Federation
Competing Interests: not
Russian Federation
Natalia V. Matveeva
295051, Simferopol, Lenin boulevard, 5/7
Competing Interests: not
References
1. Rheumatology: Russian Clinical Guidelines. Edited by Nasonov EL. Moscow: GEOTAR-Media; 2017: 464. (In Russ.).
2. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563-2574. DOI: 10.1056/NEJMra1406182
3. Erdes SF. Updated ASAS-EULAR guidelines for axial spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):508-509 (In Russ.). DOI: 10.14412/1995-4484-2016-508-509
4. van der Heijde D, Ramiro S, Landewc R, et al. 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991. DOI: 10.1136/ANNRHEUMDIS-2016-210770
5. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582-591. DOI: 10.1002/art.20852
6. Yates M, Hamilton LE, Elender F, et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J Rheumatol. 2015;42(7):1177-1185. DOI: 10.3899/jrheum.141335
7. Navarro-Compan V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30(7):993-996. DOI: 10.1007/s10067-011-1722-5
8. De Stefano R, Frati E, De Quattro D, et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol. 2014;33(5):707-711. DOI: 10.1007/s10067-013-2372-6
9. Sebastian A, Wojtala P, Lubinski L, et al. Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitirs therapy. Reumatologia. 2017;55(4):157-162. DOI: 10.5114/reum.2017.69775
10. Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200-1209. DOI: 10.1093/rheumatology/keu461
11. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439-R444. DOI: 10.1186/ar1693
12. Landewc R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (NR-AXSPA). Ann Rheum Dis. 2018;77:213. DOI: 10.1136/annrheumdis-2012-201766
13. Anderson JJ, Baron G, van der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876-1886. DOI: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
14. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368. DOI: 10.1002/art.1780270401
15. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-1818. DOI: 10.1136/ARD.2008.100826
16. Lee H, Jung Y, Song S, et al. Dosage and duration of etanercept therapy for ankylosing spondylitis: A meta-analysis. Int J Technol Assess Health Care. 2017;33(1):69-75. DOI: 10.1017/S0266462317000150
17. Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212-1215. DOI: 10.1136/annrheumdis-2011-201010
18. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloar-thritis: Results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815-822. DOI: 10.1136/ANNRHEUMDIS-2012-201766
19. Haibel H, Heldmann F, Listing J, et al. Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum. 2013;65(8):2211-2213. DOI: 10.1002/art.38014
20. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187-1193. DOI: 10.1016/s0140-6736(02)08215-6
21. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month openlabel study. Rheumatology (Oxford). 2002;41(11):1280-1285. DOI: 10.1093/rheumatology/41.11.1280
22. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667-1675. DOI: 10.1002/art.11017
Review
For citations:
Petrov A.V., Shevnina Ya.O., Gaffarova A.S., Matveeva N.V. Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data. Rheumatology Science and Practice. 2020;58(6):691-694. (In Russ.) https://doi.org/10.47360/1995-4484-2020-691-694
Views:
466
Email this article 